Chrysophanol 100 mg | Purity Not Available
TargetMol
Chrysophanol (Turkey Rhubarb) is an EGFR/mTOR pathway inhibitor, which can be found in rhubarb, and sorrel.
More Information Supplier PageChrysophanol
Search Results
3-Nitropropanoic acid 100 mg | 99.85%
TargetMol
3-Nitropropanoic acid
(±)-Abscisic acid 10 mg | 99.45%
TargetMol
(±)-Abscisic acid
(±)-Abscisic acid 25 mg | 99.45%
TargetMol
(±)-Abscisic acid
(±)-Abscisic acid 50 mg | 99.45%
TargetMol
(±)-Abscisic acid
Avitinib 10 mg | 100.00%
TargetMol
Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This […]
More Information Supplier PageAvitinib
Alvelestat 25 mg | 99.87%
TargetMol
Alvelestat is an orally bioavailable, selective and reversible inhibitor of human neutrophil elastase (NE), with potential anti-inflammatory activity.
More Information Supplier PageAlvelestat
Alvelestat 10 mg | 99.87%
TargetMol
Alvelestat is an orally bioavailable, selective and reversible inhibitor of human neutrophil elastase (NE), with potential anti-inflammatory activity.
More Information Supplier PageAlvelestat
Avitinib 5 mg | 100.00%
TargetMol
Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This […]
More Information Supplier PageAvitinib
Avitinib 50 mg | 100.00%
TargetMol
Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This […]
More Information Supplier PageAvitinib